1Rixe O,Ortuzar W,Alvarez M,et al.Oxaliplatin,tetraplatin,cisplatin,and carboplat in:spectrum of activity in drug resistant cell lines and in the cell lines of the national cancer institute′s anticancer drug screen panel[J].Biochem Pharmacol,1996,52(12):1855.
2Misset JL.Oxaliplatin in practice[J].Br J Cancer,1998,77(S4):4.
3Gamelin E,Gamelin L,Bossi L,et al.Clinical aspects and molecular basis of oxaliplatin neurotoxicity:current management and development of preventive measures[J].Semin Oncol,2002,29(S15):21.
6Extra JM,Marty M,Brienza S,et al.Pharmacokinetics and safety profile of oxalipl atin[J].Semin Oncol,1998,25(2):13.
7Allain P,Heudi O,Cailleux A.Early biotransformations of oxaliplatin after its intravenous administration to cancer patients[J].Drug Metab Dispos,2000,28(11):1379.
9Adelsberger H,Quasthoff S,Grosskreutz J,et al.The chemotherapeutic oxaliplatin alters voltage gated Na(+) channel kinetics on rat sensory neurons[J].Eur J Pharma Col,2000,406(1):25-32.
10Grolleau F,Gamelin L,Boisdron Celle M,et al.A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage gated sodium channels[J].Neurophysiol,2001,85(5):2293-2297.
